ArticleFrontiers in immunology2026
Catastrophic antiphospholipid syndrome complicated with multiple infections: a case report.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Catastrophic antiphospholipid syndrome (CAPS) is a rare and life-threatening manifestation of antiphospholipid syndrome (APS), which is frequently later diagnosed with high mortality. Case report: A 54-year-old woman with a history of livedo reticularis presented with fever for four days, hematuria for two days, and impaired consciousness and petechiae for one day. Laboratory tests indicated thrombocytopenia, anemia, elevated indirect bilirubin and lactate dehydrogenase levels, as well as elevated free hemoglobin, isolated C3d positivity on direct antiglobulin test, and positive lupus anticoagulant and anti-cardiolipin IgG (aCL-IgG). A diagnosis of autoimmune hemolytic anemia and thrombocytopenia was established, and high-dose methylprednisolone combined with intravenous immunoglobulin therapy was initiated. On day 4, a tricuspid valve thrombus was detected and argatroban was initiated. Although the isolated LA positivity and low-titer aCL-IgG did not fulfill classic APS criteria, the definitive thrombosis led us to strongly suspect quasi-seronegative APS, prompting an increased methylprednisolone dose. On day 6, the platelet count dropped again, and a diagnosis of CAPS was suspected, prompting the administration of methylprednisolone pulse therapy along with plasma exchange. On day 6, the platelet count dropped again, and the patient received methylprednisolone pulse along with plasma exchange treatment. On day 10, leukopenia complicated mixed bacterial infections were developed. On day 11, subarachnoid hemorrhage occurred, leading to discontinuation of anticoagulant. Ultimately, the patient died with the worsened infections. Autopsy revealed extensive thrombosis and severe disseminated mixed infections. Conclusions: Early manifestations of CAPS may be atypical, so early identification is crucial for treatment. Following steroid pulse therapy, vigilance for fungal infections is essential, with empirical antifungal therapy initiated when necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.